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Should the targeted value of the
phosphate be reviewed in the
normal range from the viewpoint
of vascular calcification?
To the Editor: In patients with chronic kidney disease stage
(CKD) 5D, the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines suggest lowering elevated phosphorus
(P) levels toward the normal range. In patients on dialysis,
multiple studies from different parts of the world have shown
that higher levels of serum P have been associated with an
increased relative risk (RR) of mortality. The inﬂection point
or range in which P level becomes signiﬁcantly associated
with increased all-cause mortality varies among studies for
the reasons cited above: 5.0–5.5mg/dl (1.6–1.8mmol/l),
45.5mg/dl (41.8mmol/l), 6.0–7.0mg/dl (1.9–2.3mmol/l),
and 46.5mg/dl (42.1mmol/l). However, most of these
multiple studies did not show signiﬁcant differences between
the normal range and moderately high P levels in mortality.1
As per the KDOQI Clinical Practice Guidelines, serum levels
of P should be maintained between 3.5 and 5.5mg/dl
(1.13 and 1.78mmol/l) in CKD patients with kidney failure
(stage 5). These values were set from the viewpoint of
mortality. The cross-sectional study that met the inclusion
criteria evaluated the association of serum P levels with
extraskeletal outcomes. In the KDOQI Clinical Practice
Guidelines, a reference serum P level range of 4.6–5.5mg/dl
(1.49–1.78mmol/l) is stated, and the RR of mortality is
suggested to increase with serum P levels 46.5mg/dl
(2.10mmol/l).2
If the management-targeted value of P level is set from the
view of not mortality but vascular and valvular calciﬁcation, it
should be set lower.
We reported the associations of serum P concentrations
with coronary artery calciﬁcation by 16-slice multislice
computer tomography (MSCT) in ESRD patients. For this,
we recruited 31 ESRD patients (18 male and 13 female, mean
age 62±12 years, mean duration of dialysis 6.6±6.6 years).
In 16-slice MSCT, the calciﬁed coronary lesions were found in
24 cases (80%), including 13 cases with severe degree of
calciﬁcation as indicated by the coronary artery calciﬁcation
score (more than 400). However, the serum P level was
45.6mg/dl in 39% of the patients in this sample.3 Therefore,
we examined the relationship between vascular calciﬁcation
and serum P level using the autopsy records of ESRD patients.
We analyzed the autopsy records of 224 ESRD patients (age
53.8±17.0 years, sex (M/F) 158/66, duration of dialysis
3.41±4.59 years). On drawing the receiver operating
characteristic curve, the cut-off point of the P level was
4.8mg/dl (sensitivity 77.8%, speciﬁcity 66.7%) (Figure 1).
This value (4.8mg/dl) was almost the normal P level,
according to the European Best Practice Guidelines. At
present it is possible to use cinacalcet and lanthanum
carbonate, which we were unable to use in 2003 when the
KDOQI Clinical Practice Guidelines were presented, and
control the serum P level easily. So, the targeted value of the P
should be reviewed lower to normal range.
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The Authors Reply: Yokoyama et al.1 take issue with our
recommendation to lower elevated phosphorus levels toward
the normal range in patients with chronic kidney disease
(CKD) stage 5D (2C), as reported in the KDIGO (Kidney
Disease: Improving Global Outcomes) clinical practice
guidelines for the diagnosis, evaluation, prevention, and
treatment of Chronic Kidney Disease-Mineral and Bone
Disorder (CKD-MBD), chapter 4.1.1.2 The strength of this
l e t te r to the ed i to r http://www.kidney-international.org
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Figure 1 |The receiver operating characteristic (ROC) curves of
coronary artery calcification in autopsy samples and serum
phosphorus level in end-stage renal disease (ESRD) patients.
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